Based on previous research, our work focuses on the positive effect of SHTXF on IR by modulating the InR/PI3K/Akt signaling pathway, not only indicating potential drug targets but also providing key insights for the clinical treatment of T2DM and related metabolic diseases. The gene discussed is AKT1; the disease is Other metabolic disease.